Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Int. J. Mol. Sci. 2013, 14(8), 16656-16671; doi:10.3390/ijms140816656
Article

Androgen Receptor Phosphorylation at Serine 308 and Serine 791 Predicts Enhanced Survival in Castrate Resistant Prostate Cancer Patients

1
, 1
, 1
, 1
, 1
, 2
, 3
 and 1,*
Received: 22 April 2013; in revised form: 22 July 2013 / Accepted: 26 July 2013 / Published: 13 August 2013
(This article belongs to the Special Issue Molecular Research in Urology)
View Full-Text   |   Download PDF [1992 KB, uploaded 19 June 2014]
Abstract: We previously reported that AR phosphorylation at serine 213 was associated with poor outcome and may contribute to prostate cancer development and progression. This study investigates if specific AR phosphorylation sites have differing roles in the progression of hormone naïve prostate cancer (HNPC) to castrate resistant disease (CRPC). A panel of phosphospecific antibodies were employed to study AR phosphorylation in 84 matched HNPC and CRPC tumours. Immunohistochemistry measured Androgen receptor expression phosphorylated at serine residues 94 (pAR94), 308 (pAR308), 650(pAR650) and 791 (pAR791). No correlations with clinical parameters were observed for pAR94 or pAR650 in HNPC or CRPC tumours. In contrast to our previous observation with serine 213, high pAR308 is significantly associated with a longer time to disease specific death (p = 0.011) and high pAR791 expression significantly associated with a longer time to disease recurrence (p = 0.018) in HNPC tumours and longer time to death from disease recurrence (p = 0.040) in CRPC tumours. This observation in CRPC tumours was attenuated in high apoptotic tumours (p = 0.022) and low proliferating tumours (p = 0.004). These results demonstrate that understanding the differing roles of AR phosphorylation is necessary before this can be exploited as a target for castrate resistant prostate cancer.
Keywords: androgen receptor; phosphorylation; hormone naive prostate cancer; castrate resistant prostate cancer androgen receptor; phosphorylation; hormone naive prostate cancer; castrate resistant prostate cancer
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

McCall, P.; Adams, C.E.; Willder, J.M.; Bennett, L.; Qayyum, T.; Orange, C.; Underwood, M.A.; Edwards, J. Androgen Receptor Phosphorylation at Serine 308 and Serine 791 Predicts Enhanced Survival in Castrate Resistant Prostate Cancer Patients. Int. J. Mol. Sci. 2013, 14, 16656-16671.

AMA Style

McCall P, Adams CE, Willder JM, Bennett L, Qayyum T, Orange C, Underwood MA, Edwards J. Androgen Receptor Phosphorylation at Serine 308 and Serine 791 Predicts Enhanced Survival in Castrate Resistant Prostate Cancer Patients. International Journal of Molecular Sciences. 2013; 14(8):16656-16671.

Chicago/Turabian Style

McCall, Pamela; Adams, Claire E.; Willder, Jennifer M.; Bennett, Lindsay; Qayyum, Tahir; Orange, Clare; Underwood, Mark A.; Edwards, Joanne. 2013. "Androgen Receptor Phosphorylation at Serine 308 and Serine 791 Predicts Enhanced Survival in Castrate Resistant Prostate Cancer Patients." Int. J. Mol. Sci. 14, no. 8: 16656-16671.



Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert